Treatment trials in progressive MS—current challenges and future directions
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment trials in progressive MS—current challenges and future directions
Authors
Keywords
-
Journal
Nature Reviews Neurology
Volume 9, Issue 9, Pages 496-503
Publisher
Springer Nature
Online
2013-07-30
DOI
10.1038/nrneurol.2013.148
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Multiple Sclerosis Functional Composite: A clinically meaningful measure of disability
- (2015) C. H. Polman et al. NEUROLOGY
- Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
- (2012) Wolfgang Brück et al. ACTA NEUROPATHOLOGICA
- Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
- (2012) Jack Antel et al. ACTA NEUROPATHOLOGICA
- Cortical lesion load associates with progression of disability in multiple sclerosis
- (2012) M. Calabrese et al. BRAIN
- Immune Therapy of Multiple Sclerosis - Future Strategies
- (2012) Sven G. Meuth et al. CURRENT PHARMACEUTICAL DESIGN
- From bench to MS bedside: Challenges translating biomarker discovery to clinical practice
- (2012) Sathyanath Rajasekharan et al. JOURNAL OF NEUROIMMUNOLOGY
- Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
- (2012) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Measurement and clinical effect of grey matter pathology in multiple sclerosis
- (2012) Jeroen JG Geurts et al. LANCET NEUROLOGY
- Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures
- (2012) D Ontaneda et al. Multiple Sclerosis Journal
- Epigenetic changes in patients with multiple sclerosis
- (2012) Marcus W. Koch et al. Nature Reviews Neurology
- Progressive multiple sclerosis: pathology and pathogenesis
- (2012) Hans Lassmann et al. Nature Reviews Neurology
- Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis
- (2012) Roberto Madeddu et al. NEUROLOGICAL SCIENCES
- Remyelination Therapy for Multiple Sclerosis
- (2012) Michael B. Keough et al. Neurotherapeutics
- Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis
- (2012) Marcus W. Koch et al. TRENDS IN MOLECULAR MEDICINE
- Impaired neurosteroid synthesis in multiple sclerosis
- (2011) Farshid Noorbakhsh et al. BRAIN
- Fingolimod modulates microglial activation to augment markers of remyelination
- (2011) Samuel J Jackson et al. Journal of Neuroinflammation
- Oral treatment for multiple sclerosis
- (2011) Joep Killestein et al. LANCET NEUROLOGY
- Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
- (2011) Gavin Giovannoni et al. LANCET NEUROLOGY
- Evidence for a two-stage disability progression in multiple sclerosis
- (2010) E. Leray et al. BRAIN
- The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
- (2010) Antonio Scalfari et al. BRAIN
- Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline
- (2010) Sarah A. Morrow et al. CLINICAL NEUROPSYCHOLOGIST
- Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation
- (2010) Henrik Wilms et al. Journal of Neuroinflammation
- Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
- (2010) Raju Kapoor et al. LANCET NEUROLOGY
- Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
- (2010) LVAE Bosma et al. Multiple Sclerosis Journal
- A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis
- (2010) Jeremy Chataway et al. Multiple Sclerosis Journal
- Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors
- (2009) Mohamed Ouardouz et al. ANNALS OF NEUROLOGY
- Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis
- (2009) Laura Garay et al. BRAIN RESEARCH
- Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity
- (2009) E M Mowry et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- The search for responsive clinical endpoints in primary progressive multiple sclerosis
- (2009) LVAE Bosma et al. Multiple Sclerosis Journal
- The natural history of primary progressive multiple sclerosis
- (2009) M. Koch et al. NEUROLOGY
- Remyelination protects axons from demyelination-associated axon degeneration
- (2008) K. A. Irvine et al. BRAIN
- Therapeutic Potential of Fluoxetine in Neurological Disorders
- (2008) Jop P. Mostert et al. CNS Neuroscience & Therapeutics
- LINGO-1 antagonists as therapy for multiple sclerosis:in vitroandin vivoevidence
- (2008) Richard A Rudick et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity
- (2008) R.E. Gonsette JOURNAL OF THE NEUROLOGICAL SCIENCES
- Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
- (2008) D. R. Altmann et al. NEUROLOGY
- MRI as an outcome in multiple sclerosis clinical trials
- (2008) M. Daumer et al. NEUROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started